Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2022-02-16 00:00:00 ET · period of report 2022-02-15 · accession 0000886163-22-000021 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2022-02-16 | 2022-02-15 | LGND | Korenberg Matthew E | EVP, CFO, Fin, Strategy | F - Tax | $123.68 | -3,407 | 46.8K | -7% | -$421.4K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-02-15 | F | D | 1,532 | $123.68 | 44,306 | D | — | — | (F3) Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/03/2021. |
| 2 | Common | Common Stock | 2022-02-15 | F | D | 969 | $123.68 | 45,838 | D | — | — | (F2) Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/13/2020. |
| 3 | Common | Common Stock | 2022-02-15 | F | D | 906 | $123.68 | 46,807 | D | — | — | (F1) Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/11/2019. |